Works matching IS 11738804 AND DT 2023 AND VI 37 AND IP 3

Results: 11

Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus.

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 295, doi. 10.1007/s40259-023-00596-4

By:

Verwey, Charl;
Madhi, Shabir A.

Publication type:

Article

Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery.

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 353, doi. 10.1007/s40259-023-00595-5

By:

Mohammadi, Amir Hossein;
Ghazvinian, Zeinab;
Bagheri, Fatemeh;
Harada, Masako;
Baghaei, Kaveh

Publication type:

Article

Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus.

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 331, doi. 10.1007/s40259-023-00594-6

By:

Huang, Mingshu;
Chen, Weixing;
Wang, Min;
Huang, Yisheng;
Liu, Hongyu;
Ming, Yue;
Chen, Yuanxin;
Tang, Zhengming;
Jia, Bo

Publication type:

Article

Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 375, doi. 10.1007/s40259-023-00590-w

By:

Gusarova, Valentina D.;
Smolov, Maxim A.;
Lyagoskin, Ivan V.;
Degterev, Maksim B.;
Rechetnik, Elizaveta V.;
Rodionov, Alexander V.;
Pantyushenko, Marina S.;
Shukurov, Rahim R.

Publication type:

Article

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 409, doi. 10.1007/s40259-023-00589-3

By:

Peng, Kuan;
Blais, Joseph E.;
Pratt, Nicole L.;
Guo, Jeff Jianfei;
Hillen, Jodie B.;
Stanford, Tyman;
Ward, Michael;
Lai, Edward Chia-Cheng;
Shin, Ju-Young;
Tong, Xinning;
Fan, Min;
Cheng, Franco W. T.;
Wu, Jing;
Yeung, Winnie W. Y.;
Lau, Chak-Sing;
Leung, Wai Keung;
Wong, Ian C. K.;
Li, Xue

Publication type:

Article

Correction to: Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.

Published in:

2023

By:

Rupert, Douglas J.;
Jordan, Alyssa M.;
Ziemian, Marina A.;
Brown, Rachel M.;
Fleming, Neil S.;
Lefebvre, R. Craig

Publication type:

Correction Notice

Targeting IL-36 in Inflammatory Skin Diseases.

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 279, doi. 10.1007/s40259-023-00587-5

By:

Fukaura, Ryo;
Akiyama, Masashi

Publication type:

Article

Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 421, doi. 10.1007/s40259-023-00586-6

By:

Shao, Taihang;
Zhao, Mingye;
Liang, Leyi;
Tang, Wenxi

Publication type:

Article

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 311, doi. 10.1007/s40259-023-00585-7

By:

Arjomandnejad, Motahareh;
Dasgupta, Ishani;
Flotte, Terence R.;
Keeler, Allison M.

Publication type:

Article

Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System.

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 397, doi. 10.1007/s40259-023-00584-8

By:

Jourdain, Hugo;
Hoisnard, Léa;
Sbidian, Emilie;
Zureik, Mahmoud

Publication type:

Article

Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.

Published in:

BioDrugs, 2023, v. 37, n. 3, p. 433, doi. 10.1007/s40259-023-00582-w

By:

Stebbing, Justin;
Baranau, Yauheni;
Baryash, Valery;
Moiseyenko, Vladimir;
Boliukh, Dmytro;
Antone, Nicoleta;
Manikhas, Alexey;
Chornobai, Anatolii;
Park, Taehong;
Baek, Eric Hyungseok;
Lee, Jaeyong;
Choi, Jiin;
Kim, Nahyun;
Ahn, Keumyoung;
Lee, Sang Joon;
Kim, Sunghyun

Publication type:

Article